Limits...
Inhaled insulin: A "puff" than a "shot" before meals.

Brashier DB, Khadka A, Anantharamu T, Sharma AK, Gupta AK, Sharma S, Dahiya N - J Pharmacol Pharmacother (2015 Jul-Sep)

Bottom Line: The large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium facilitates systemic delivery of insulin via pulmonary administration.Inhaled insulin has been recently approved by Food and Drug Administration (FDA).It is a novel, rapid-acting inhaled insulin with a pharmacokinetic profile that is different from all other insulin products and comparatively safer than the previous failed inhaled insulin (Exubera).

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India.

ABSTRACT
Diabetes is a metabolic disorder characterized by relative or absolute deficiency of insulin, resulting in hyperglycemia. The main treatment of diabetes relies on subcutaneous insulin administration by injection or continuous infusion to control glucose levels, besides oral hypoglycemic agents for type 2 diabetes. Novel routes of insulin administration are an area of research in the diabetes field as insulin injection therapy is burdensome and painful for many patients. Inhalational insulin is a potential alternative to subcutaneous insulin in the management of diabetes. The large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium facilitates systemic delivery of insulin via pulmonary administration. Inhaled insulin has been recently approved by Food and Drug Administration (FDA). It is a novel, rapid-acting inhaled insulin with a pharmacokinetic profile that is different from all other insulin products and comparatively safer than the previous failed inhaled insulin (Exubera).

No MeSH data available.


Related in: MedlinePlus

Insulin (Exubera) inhaler
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4544132&req=5

Figure 5: Insulin (Exubera) inhaler

Mentions: The most common adverse reactions include hypoglycemia, cough, throat pain and irritation. There is some evidence reduction in FEV1 of lung function, but overall long-term effects and the need for withdrawal has not yet been established as it is for its predecessor Exubera [Figure 5]. Serious risk includes bronchospasm in patients with asthma, COPD and smokers.[17202122]


Inhaled insulin: A "puff" than a "shot" before meals.

Brashier DB, Khadka A, Anantharamu T, Sharma AK, Gupta AK, Sharma S, Dahiya N - J Pharmacol Pharmacother (2015 Jul-Sep)

Insulin (Exubera) inhaler
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4544132&req=5

Figure 5: Insulin (Exubera) inhaler
Mentions: The most common adverse reactions include hypoglycemia, cough, throat pain and irritation. There is some evidence reduction in FEV1 of lung function, but overall long-term effects and the need for withdrawal has not yet been established as it is for its predecessor Exubera [Figure 5]. Serious risk includes bronchospasm in patients with asthma, COPD and smokers.[17202122]

Bottom Line: The large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium facilitates systemic delivery of insulin via pulmonary administration.Inhaled insulin has been recently approved by Food and Drug Administration (FDA).It is a novel, rapid-acting inhaled insulin with a pharmacokinetic profile that is different from all other insulin products and comparatively safer than the previous failed inhaled insulin (Exubera).

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India.

ABSTRACT
Diabetes is a metabolic disorder characterized by relative or absolute deficiency of insulin, resulting in hyperglycemia. The main treatment of diabetes relies on subcutaneous insulin administration by injection or continuous infusion to control glucose levels, besides oral hypoglycemic agents for type 2 diabetes. Novel routes of insulin administration are an area of research in the diabetes field as insulin injection therapy is burdensome and painful for many patients. Inhalational insulin is a potential alternative to subcutaneous insulin in the management of diabetes. The large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium facilitates systemic delivery of insulin via pulmonary administration. Inhaled insulin has been recently approved by Food and Drug Administration (FDA). It is a novel, rapid-acting inhaled insulin with a pharmacokinetic profile that is different from all other insulin products and comparatively safer than the previous failed inhaled insulin (Exubera).

No MeSH data available.


Related in: MedlinePlus